Natural killer-cell malignancies: Diagnosis and treatment

Leukemia

Volumn 19, Issue 12, 2005, Pages 2186-2194

  Kwong, Y L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Nasal; Natural kille cell lymphoma; Non nasal aggressive

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CARMUSTINE; CD2 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; STEROID; VINCRISTINE; VIRUS DNA;

ADVANCED CANCER; CANCER CLASSIFICATION; CANCER INVASION; CANCER STAGING; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; LIVER DYSFUNCTION; NATURAL KILLER CELL; NOSE TUMOR; PATIENT CODING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; RASH; REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE RECEPTOR GENE; TREATMENT OUTCOME; TUMOR LOCALIZATION; VIRUS INFECTION; VIRUS LOAD;

EID: 28544444488     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403955     Document Type: Review

References (83)

1. Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood 1995; 85: 2654-2670.
2. Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16: 359-393.
3. Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989; 169: 2233-2238.
4. Wong KF, Chan JK, Ng CS, Lee KC, Tsang WY, Cheung MM. CD56 (NKH1)-positive hematolymphoid malignancies: An aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum Pathol 1992; 23: 798-804.
5. Kern WF, Spier CM, Hanneman EH, Miller TP, Matzner M, Grogan TM. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: A rare variant with a propensity for unusual sites of involvement. Blood 1992; 79: 2432-2437.
6. Chan JK, Tsang WY, Ng CS. Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: The neoplastic cells are often CD3 epsilon+. Blood 1996; 87: 839-841.
7. Chan JK, Jaffe ES, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001, pp 204-207.
8. Chan JK, Wong KF, Jaffe ES, Ralfkiaer E. Aggressive NK-cell leukaemia. In Jaffe ES, Harris ML, Stein H, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001, pp 198-200.
9. Kwong YL, Chan AC, Liang RH. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol Oncol 1997; 15: 71-79.
10. Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: A distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol 2003; 40: 221-232.
11. Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: Clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70-77.
12. Cuadra-Garcia I, Proulx GM, Wu CL, Wang CC, Pilch BZ, Harris NL et al. Sinonasal lymphoma: A clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol 1999; 23: 1356-1369.
13. Gaal K, Sun NC, Hernandez AM, Arber DA. Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol 2000; 24: 1511-1517.
14. Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR et al. Angiocentric lymphoma of the head and neck: Patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 54-63.
15. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R et al. Primary nasal natural killer cell lymphoma: Long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216-221.
16. Chim CS, Ooi GC, Shek TW, Liang R, Kwong YL. Lethal midline granuloma revisited: Nasal T/natural-killer cell lymphoma. J Clin Oncol 1999; 17: 1322-1325.
17. Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: A clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 4501-4513.
18. Chim CS, Au WY, Poon C, Ooi GC, Lam CC, Kwong YL. Primary natural killer cell lymphoma of skeletal muscle. Histopathology 2002; 41: 371-374.
19. Chim CS, Choy C, Liang R, Kwong YL. Isolated uterine relapse of nasal T/ Nk cell lymphoma. Leukemia Lymphoma 1999; 34: 629-632.
20. Chim CS, Ma ES, Loong F, Kwong YL. Diagnostic cues for natural killer cell lymphoma: Primary nodal presentation and the role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in detecting occult bone marrow involvement, J Clin Pathol 2005; 58: 443-445.
21. Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK et al. CD56+ NK lymphomas: Clinicopathological features and prognosis. Br J Haematol 1997; 97: 821-829.
22. Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, er al, NK-cell Tumor Study Group. Aggressive natural killer-cell leukemia revisited: Large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763-770.
23. Wong KF, Chan JK, Cheung MM, So JC. Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J Clin Pathol 2001; 115: 266-270.
24. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
25. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9: 717-720.
26. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: A single center experience of 10 years. Ann Oncol 2005; 16: 206-214.
27. Kawa-Ha K, Ishihara S, Ninomiya T, Yumura-Yagi K, Hara J, Murayama F et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989; 84: 51-55.
28. Hart DN, Baker BW, Inglis MJ, Nimmo JC, Starling GC, Deacon E et al. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood 1992; 79: 2116-2123.
29. Arber DA, Weiss LM, Albujar PF, Chen YY, Jaffe ES. Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 1993; 17: 392-399.
30. Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, Krenacs L, Kingma DW, Raffeld M et al. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol 1998; 11: 754-761.
31. Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol 2002; 17: 539-554.
32. Chan JK, Yip TT, Tsang WY, Ng CS, Lau WH, Poon YF et al. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 1994; 18: 938-946.
33. Sakata K, Hareyama M, Ohuchi A, Sido M, Nagakura H, Morita K et al. Treatment of lethal midline granuloma type nasal T-cell lymphoma. Acta Oncol 1997; 36: 307-311.
34. Shikama N, Izuno I, Oguchi M, Gomi K, Sone S, Takei K et al. Clinical stage IE primary lymphoma of the nasal cavity: Radiation therapy and chemotherapy. Radiology 1997; 204: 467-470.
35. Li YX, Coucke PA, Li JY, Gu DZ, Liu XF, Zhou LQ et al. Primary non-Hodgkin's lymphoma of the nasal cavity: Prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998; 83: 449-456.
36. Lei KI, Suen JJ, Hui P, Tong M, Li W, Yau SH. Primary nasal and nasopharyngeal lymphomas: A comparative study of clinical presentation and treatment outcome. Clin Oncol (R Coll Radiol) 1999; 11: 379-387.
37. Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY et al. CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349-352.
38. You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: A single institute survey in Taiwan. Ann Oncol 2004; 15: 618-625.
39. Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK et al. Angiocentric T-cell and NK/T-cell lymphomas: Radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004; 59: 1127-1137.
40. Robbins KT, Fuller LM, Vlasak M, Osborne B, Jing BS, Velasquez WS et al. Primary lymphomas of the nasal cavity and paranasal sinuses. Cancer 1985; 56: 814-819.
41. Ooi GC, Chim CS, Liang R, Tsang KW, Kwong YL. Nasal T-cell/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity. Am J Roentgenol 2000; 174: 1141-1145.
42. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
43. Gallagher A, Armstrong AA, MacKenzie J, Shield L, Khan G, Lake A et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999; 84: 442-448.
44. Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003; 63: 2028-2032.
45. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 243-249.
46. Ribrag V, Ell Hajj M, Janot F, Girinsky T, Domenge C, Schwaab G et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001; 15: 1123-1126.
47. Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/ T-cell or T-cell lymphoma. Cancer 2004; 100: 366-375.
48. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: Clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182-190.
49. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999; 93: 599-606.
50. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 2351-2356.
51. Ebihara Y, Manabe A, Tanaka R, Yoshimasu T, Ishikawa K, Iseki T et al. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation. Bone Marrow Transplant 2003; 31: 1169-1171.
52. Okamura T, Kishimoto T, Inoue M, Honda M, Yamashita N, Wakiguchi H et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant 2003; 31: 105-111.
53. Siu LL, Chan JK, Wong KF, Kwong YL. Specific patterns of gene methylation in natural killer cell lymphomas: P73 is consistently involved. Am J Pathol 2002; 160: 59-66.
54. Siu LL, Chan JK, Wong KF, Choy C, Kwong YL. Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol 2003; 122: 70-77.
55. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F et al. Fas ligand in human serum. Nat Med 1996; 2: 317-322.
56. Kato K, Ohshima K, Ishihara S, Anzai K, Suzumiya J, Kikuchi M. Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. Br J Haematol 1998; 103: 1164-1166.
57. Niitsu N, Okamoto M, Honma Y, Nakamine H, Tamaru JI, Nakamura S, et al, Adult Lymphoma Treatment Study Group. Serum levels of the nm23-H1 protein and their clinical implication in extranodal NK/T-cell lymphoma. Leukemia 2003; 17: 987-990.
58. Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: A progress report on its value. Ann Oncol 2003; 14: 1673-1676.
59. Okamura T, Kishimoto T, Inoue M, Honda M, Yamashita N, Wakiguchi H et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant 2003; 31: 105-111.
60. Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 150: 561-567.
61. Obama K, Tara M, Niina K. L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 2003; 78: 248-250.
62. Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003; 78: 163-167.
63. Matsumoto Y, Nomura K, Kanda-Akano Y, Fujita Y, Nakao M, Ueda K et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leukemia Lymphoma 2003; 44: 879-882.
64. Wong KF, Chan JK, Kwong YL. Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/ leukaemia. Br J Haematol 1997; 98: 922-926.
65. Zhang Y, Wong KF, Siebert R, Matthiesen P, Harder S, Eimermacher H et al. Chromosome aberrations are restricted to the CD56+, CD3- tumour cell population in natural killer cell lymphomas: A combined immunophenotyping and FISH study. Br J Haematol 1999; 105: 737-742.
66. Zhang Y, Matthiesen P, Harder S, Siebert R, Castoldi G, Calasanz MJ et al. A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosomes Cancer 2000; 27: 52-58.
67. Sun HS, Su IJ, Lin YC, Chen JS, Fang SY. A 2.6Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma. Br J Haematol 2003; 122: 590-599.
68. Siu LL, Wong KF, Chan JK, Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 1999; 155: 1419-1425.
69. Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol 2000; 157: 1803-1809.
70. Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 2000; 60: 2345-2347.
71. Kawamata N, Inagaki N, Mizumura S, Sugimoto KJ, Sakajiri S, Ohyanagi-Hara M et al. Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders. Eur J Haematol 2005; 74: 424-429.
72. Shen L, Liang AC, Lu L, Au WY, Kwong YL, Liang RH et al. Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma. Am J Pathol 2002; 161: 2123-2131.
73. Schrader C, Janssen D, Kneba M, Lennert K. A 38-year history of natural-killer-cell lymphoma. N Engl J Med 2004; 350: 418-419.
74. Hsi ED, Picken MM, Alkan S. Post-transplantation lymphoproliferative disorder of the NK-cell type: A case report and review of the literature. Mod Pathol 1998; 11: 479-484.
75. Kwong YL, Lam CC, Chan TM. Post-transplantation lymphoproliferative disease of natural killer cell lineage: A clinicopathological and molecular analysis. Br J Haematol 2000; 110: 197-202.
76. Tsao L, Draoua HY, Mansukhani M, Bhagat G, Alobeid B. EBV-associated, extranodal NK-cell lymphoma, nasal type of the breast, after heart transplantation. Mod Pathol 2004; 17: 125-130.
77. Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-286.
78. Kanno H, Onodera H, Endo M, Maeda F, Chida S, Akasaka T et al. Vascular lesion in a patient of chronic active Epstein-Barr virus infection with hypersensitivity to mosquito bites: Vasculitis induced by mosquito bite with the infiltration of nonneoplastic Epstein-Barr virus-positive cells and subsequent development of natural killer/T-cell lymphoma with angiodestruction. Hum Pathol 2005; 36: 212-218.
79. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100: 4059-4066.
80. Ebihara Y, Manabe A, Tanaka R, Yoshimasu T, Ishikawa K, Iseki T et al. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation. Bone Marrow Transplant 2003; 31: 1169-1171.
81. Chan JK, Jaffe ES, Ralfkiaer E. Blastic NK-cell lymphoma. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001, pp 214-215.
82. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
83. Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: A retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004; 15: 1097-1108.